Moreover, inhibitors of CYP19 aromatase are frequently used for endocrine therapy of breast cancer patients, while the role of genetic variability of the target gene in the treatment efficacy or adverse effects is yet unexploited for therapeutic decisions [11]. This evidence concerns the gene CYP19A1 and breast carcinoma.